Shionogi
Clinical trials sponsored by Shionogi, explained in plain language.
A Japanese pharmaceutical company focused on infectious diseases and pain management.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can an oral pill boost muscle strength in pompe disease?
Disease control Not yet recruitingThis study tests the long-term safety and effectiveness of an experimental oral drug called S-606001 in adults with late-onset Pompe disease, a genetic condition that causes progressive muscle weakness. Participants who completed a prior S-606001 study can join, and they will rec…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new pill shorten COVID-19 symptoms?
Disease control Not yet recruitingThis phase 3 trial is testing whether the oral drug secutrelvir can help people with COVID-19 recover faster. The study involves about 1,200 nonhospitalized participants aged 12 to 75 who start treatment within 48 hours of symptom onset. Half will receive secutrelvir and half a p…
Phase: PHASE3 • Sponsor: Shionogi • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new pill keep High-Risk COVID-19 patients out of the hospital?
Disease control Not yet recruitingThis phase 3 trial is testing whether the oral antiviral secutrelvir can prevent severe COVID-19 in people who are at high risk for complications. Participants with mild symptoms and confirmed SARS-CoV-2 infection will receive either secutrelvir or a placebo. The study will measu…
Phase: PHASE3 • Sponsor: Shionogi • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC